The rates of adverse events of pancreatitis
(Table S11 in the Supplementary Appendix) and
neoplasms were calculated in terms of 100 patientyears
at risk, covering the period from the start
of treatment until the final contact with the
patient (including events that occurred during
the second randomized period after the end of
the 56-week main study and those that occurred
15 days or more after the last day the study drug
was received). Overall, 11 cases of pancreatitis
were confirmed by adjudication; these cases occurred
in 10 of 2481 patients in the liraglutide